154 related articles for article (PubMed ID: 16221104)
1. Parathyroidectomy in the calcimimetic era.
Elder GJ
Nephrology (Carlton); 2005 Oct; 10(5):511-5. PubMed ID: 16221104
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
Drüeke TB
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
[TBL] [Abstract][Full Text] [Related]
5. Calcimimetics versus parathyroidectomy: What is preferable?
Rroji M; Spasovski G
Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
[TBL] [Abstract][Full Text] [Related]
6. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
[TBL] [Abstract][Full Text] [Related]
7. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
Cunningham J; Danese M; Olson K; Klassen P; Chertow GM
Kidney Int; 2005 Oct; 68(4):1793-800. PubMed ID: 16164656
[TBL] [Abstract][Full Text] [Related]
8. The role of calcimimetics in the treatment of hyperparathyroidism.
Wüthrich RP; Martin D; Bilezikian JP
Eur J Clin Invest; 2007 Dec; 37(12):915-22. PubMed ID: 18036025
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism.
Cruzado JM; Moreno P; Torregrosa JV; Taco O; Mast R; Gómez-Vaquero C; Polo C; Revuelta I; Francos J; Torras J; García-Barrasa A; Bestard O; Grinyó JM
J Am Soc Nephrol; 2016 Aug; 27(8):2487-94. PubMed ID: 26647424
[TBL] [Abstract][Full Text] [Related]
10. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.
Evenepoel P; Sprangers B; Lerut E; Bammens B; Claes K; Kuypers D; Meijers B; Vanrenterghem Y
Clin Transplant; 2012; 26(3):393-402. PubMed ID: 22007637
[TBL] [Abstract][Full Text] [Related]
11. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
Moe SM; Chertow GM; Coburn JW; Quarles LD; Goodman WG; Block GA; Drüeke TB; Cunningham J; Sherrard DJ; McCary LC; Olson KA; Turner SA; Martin KJ
Kidney Int; 2005 Feb; 67(2):760-71. PubMed ID: 15673327
[TBL] [Abstract][Full Text] [Related]
12. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
13. Surgical parathyroidectomy versus cinacalcet therapy: in the management of secondary hyperparathyroidism.
Ghani A; Baxter P
Otolaryngol Head Neck Surg; 2012 Feb; 146(2):220-5. PubMed ID: 22075073
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
16. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.
Tominaga Y; Matsuoka S; Uno N; Sato T
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S21-6. PubMed ID: 19032523
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
19. Tertiary hyperparathyroidism resistant to cinacalcet treatment.
Okada M; Tominaga Y; Izumi K; Nobata H; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Nanmoku K; Watarai T; Uchida K
Ther Apher Dial; 2011 Jun; 15 Suppl 1():33-7. PubMed ID: 21595850
[TBL] [Abstract][Full Text] [Related]
20. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]